Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.45 |
| ▸ | CCR5 | P51681 | 3/20 | 0.45 |
| ▸ | CCR8 | P51685 | 3/20 | 0.45 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 3/20 | 0.34 |
| ▸ | NOS2 | P35228 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23169488 | 0.75 | PDE5A (0.36) | CYP2D6PDE5ACYP2C19 | |
| SCHEMBL14289229 | 0.75 | DGAT1 (0.33) | — | |
| SCHEMBL10077017 | 0.75 | RPS6KA3 (0.31) | — | |
| SCHEMBL11374405 | 0.72 | CCR1 (0.45) | CCR1CCR5CCR8CYP1A2CYP3A4 | |
| SCHEMBL30718598 | 0.71 | CCR1 (0.52) | CCR1CCR5CCR8PSMD14COPS5 | |
| SCHEMBL3152309 | 0.71 | CCR1 (0.52) | CCR1CCR5CCR8PSMD14COPS5 | |
| SCHEMBL12341885 | 0.71 | CYP17A1 (0.33) | CYP1A2CYP3A4PDE5ACYP17A1 | |
| SCHEMBL24121915 | 0.71 | CCR1 (0.45) | CCR1CCR5CCR8PSMD14COPS5 | |
| SCHEMBL18266958 | 0.71 | KDM4E (0.49) | CCR1CCR5CCR8PSMD14COPS5 | |
| SCHEMBL24352035 | 0.71 | PDE5A (0.32) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504740-A | New preparation method of palbociclin | 江苏权正检验检测有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119504739-A | Novel method for synthesizing palbociclin | 江苏权正检验检测有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20240132492-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | JINAN UNIVERSITY (CN) | 2024-04-25 | — | — | US | disclosed |
| US-8557848-B2 | 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8546420-B2 | 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120030841-A1 | Isoxazoline compounds for combating invertebrate pests | BASF SE (DE) | 2012-02-02 | — | — | US | disclosed |
| EP-2081922-B1 | 5,6-Ring annulated indole derivatives and use thereof | SCHERING CORP (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20100196319-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION | 2010-04-22 | — | — | US | disclosed |
| WO-2008082484-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196319-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | ZC3HAV1, IDO1, ZC3HAV1L | CCR1 434/4885CCR5 33/4885CCR8 626/4885 |
| US-20240132492-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | AKT3, AKT1S1, AKT2 | CCR1 4512/4885CCR5 3539/4885CCR8 4260/4885 |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | ZC3HAV1, IDO1, ZC3HAV1L | CCR1 725/4885CCR5 23/4885CCR8 939/4885 |
| US-20120030841-A1 | Isoxazoline compounds for combating invertebrate pests | PRDX5, PRDX1, PRDX2 | CCR1 4384/4885CCR5 3366/4885CCR8 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.